Clinical Trials Browser

Phase 2 × Not yet recruiting × Non-Muscle Invasive Bladder Neoplasms × Clear all

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Phase 2 Not yet recruiting

37 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07100184 2025-08-03

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Phase 2 Not yet recruiting

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06630871 2024-10-10

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Phase 2 Not yet recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06310369 2024-07-22

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Phase 2 Not yet recruiting

50 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06227065 2024-01-26

POLO

Phase 2 Not yet recruiting

28 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05996952 2023-08-18

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Phase 2 Not yet recruiting

77 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms